Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Neutropenia and BID[original query] |
---|
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer chemotherapy and pharmacology 2011 Jun 67 (6): 1323-31. Hong Junshik, Han Sae-Won, Ham Hye Seon, Kim Tae-Yong, Choi In Sil, Kim Byung-Su, Oh Do-Youn, Im Seock-Ah, Kang Gyeong Hoon, Bang Yung-Jue, Kim Tae-Y |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. British journal of cancer 2010 Mar 102 (6): 987-94. Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacía-Foncillas |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64. Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H |
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer 2013 Nov 109 (11): 2803-9. Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa |
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. Cancer chemotherapy and pharmacology 2015 Oct . Deenen Maarten J, Meulendijks Didier, Boot Henk, Legdeur Marie-Cecile J C, Beijnen Jos H, Schellens Jan H M, Cats Annemie |
Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical breast cancer 2017 9 18 (1): e135-e142. Anampa Jesus, Chen Alice, Wright John, Patel Margi, Pellegrino Christine, Fehn Karen, Sparano Joseph A, Andreopoulou Ele |
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). International journal of clinical oncology 2017 Oct 22 (5): 913-920. Ando Koji, Emi Yasunori, Suenaga Toyokuni, Hamanoue Masahiro, Maekawa Soichiro, Sakamoto Yasuo, Kai Seiichiro, Satake Hironaga, Shimose Takayuki, Shimokawa Mototsugu, Saeki Hiroshi, Oki Eiji, Sakai Kenji, Akagi Yoshito, Baba Hideo, Maehara Yoshihiko, |
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017 Oct 8 (45): 79175-79187. Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise |
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients. Cancer chemotherapy and pharmacology 2019 Aug . Nuthalapati Silpa, Stodtmann Sven, Shepherd Stacie Peacock, Ratajczak Christine K, Mensing Sven, Menon Rajeev, Xiong H |
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational new drugs 2019 10 38 (4): 1096-1107. van der Noll Ruud, Jager Agnes, Ang Joo Ern, Marchetti Serena, Mergui-Roelvink Marja W J, de Bono Johann S, Lolkema Martijn P, de Jonge Maja J A, van der Biessen Diane A, Brunetto Andre T, Arkenau Hendrik-Tobias, Tchakov Ilian, Beijnen Jos H, De Grève Jacques, Schellens Jan H |
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2020 Jun 32 (3): 370-382. Li Huiping, Liu Rongrui, Shao Bin, Ran Ran, Song Guohong, Wang Ke, Shi Yehui, Liu Jihong, Hu Wenjing, Chen Fu, Liu Xiaoran, Zhang Gairong, Zhao Chuanhua, Jia Ru, Wang Quanren, Rugo Hope S, Zhang Yifan, Li Guangze, Xu Jianmi |
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO open 2021 7 6 (4): 100212. Perez-Fidalgo J A, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio M J, González-Martín |
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
- Page last reviewed:Feb 1, 2024
- Content source: